MX2018008966A - Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. - Google Patents

Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.

Info

Publication number
MX2018008966A
MX2018008966A MX2018008966A MX2018008966A MX2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A
Authority
MX
Mexico
Prior art keywords
salt
azd9291
osimertinib
preparation
improved process
Prior art date
Application number
MX2018008966A
Other languages
English (en)
Inventor
Alistair Boyd John
Telford Alexander
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57984913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018008966(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018008966A publication Critical patent/MX2018008966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un proceso químico mejorado para la fabricación del compuesto de fórmula (I), que es útil, por ejemplo, como intermedio químico de las etapas finales en la producción de osimertinib (AZD9291) y sales farmacéuticamente aceptables del mismo. (ver Fórmula).
MX2018008966A 2016-02-01 2017-01-31 Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. MX2018008966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289390P 2016-02-01 2016-02-01
PCT/EP2017/052050 WO2017134051A1 (en) 2016-02-01 2017-01-31 Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof

Publications (1)

Publication Number Publication Date
MX2018008966A true MX2018008966A (es) 2018-09-03

Family

ID=57984913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008966A MX2018008966A (es) 2016-02-01 2017-01-31 Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.

Country Status (17)

Country Link
US (1) US11180477B2 (es)
EP (1) EP3411038B1 (es)
JP (1) JP6812449B2 (es)
KR (1) KR20180101610A (es)
CN (1) CN108495632B (es)
AR (1) AR107494A1 (es)
AU (1) AU2017214243B2 (es)
BR (1) BR112018014712B1 (es)
CA (1) CA3011809C (es)
CO (1) CO2018007008A2 (es)
ES (1) ES2834608T3 (es)
IL (1) IL260665B (es)
MX (1) MX2018008966A (es)
MY (1) MY185367A (es)
RU (1) RU2733376C2 (es)
TW (1) TWI745345B (es)
WO (1) WO2017134051A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CN107556293B (zh) * 2017-09-19 2019-12-03 福建省微生物研究所 一种奥西替尼的合成工艺
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
WO2023031316A1 (en) 2021-09-02 2023-03-09 Synthon B.V. A process for making osimertinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070401A (en) * 1972-02-19 1978-01-24 Mitsui Toatsu Chemicals Inc. Method for the preparation of a halogenated aromatic amine
CA2881993C (en) * 2011-07-27 2017-05-09 Astrazeneca Ab Substituted 4-methoxy-n3-(pyrimidin-2-yl)benzene-1,3-diamine compounds, and salts thereof
SI3157916T1 (sl) * 2014-06-19 2019-05-31 Ariad Pharmaceuticals, Inc. Heteroarilne spojine za zaviranja kinaze
CN104817541B (zh) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法

Also Published As

Publication number Publication date
CN108495632B (zh) 2021-12-31
CO2018007008A2 (es) 2018-07-19
AU2017214243A1 (en) 2018-09-06
TW201736364A (zh) 2017-10-16
RU2733376C2 (ru) 2020-10-01
US20210122734A1 (en) 2021-04-29
BR112018014712A2 (pt) 2018-12-11
JP2019508387A (ja) 2019-03-28
CN108495632A (zh) 2018-09-04
IL260665B (en) 2021-08-31
JP6812449B2 (ja) 2021-01-13
KR20180101610A (ko) 2018-09-12
AR107494A1 (es) 2018-05-02
MY185367A (en) 2021-05-11
TWI745345B (zh) 2021-11-11
CA3011809C (en) 2024-02-27
CA3011809A1 (en) 2017-08-10
ES2834608T3 (es) 2021-06-18
AU2017214243B2 (en) 2019-07-18
RU2018130327A (ru) 2020-03-04
RU2018130327A3 (es) 2020-03-26
EP3411038A1 (en) 2018-12-12
EP3411038B1 (en) 2020-09-09
US11180477B2 (en) 2021-11-23
WO2017134051A1 (en) 2017-08-10
BR112018014712B1 (pt) 2023-10-31

Similar Documents

Publication Publication Date Title
WO2016011390A8 (en) Irak4 inhibiting agents
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
MX2017003518A (es) Estimuladores de guanilato ciclasa soluble (sgc).
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
MX2017001980A (es) Derivado de quinolina muy puro y metodo para su produccion.
AU2018253590A1 (en) Imidazopyridazine compounds
MY191236A (en) Diorganylphosphinic acid salts, method for the production thereof and the use thereof
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12018500582A1 (en) Crosslinked nucleic acid guna, method for producing same, and intermediate compound
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
MX2015017156A (es) Inhibidores de bace.
WO2018029711A3 (en) Process for the preparation of venetoclax
PH12018501979A1 (en) Aminothiazole derivatives useful as antiviral agents
SG10201902609TA (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
MX2019013816A (es) Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos.
MX2018009503A (es) Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, metodos de preparacion y usos.
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
SG11201810725WA (en) Novel β-lactamase inhibitors
WO2016142819A3 (en) Novel process for the preparation of ranolazine
MX2019001228A (es) Metodo de produccion del compuesto de pirazol-amida.